Abbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 Shares
Abbott Laboratories (NYSE:ABT) insider Brian J. Blaser sold 23,866 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $55.55, for a total value of $1,325,756.30. Following the completion of the sale, the insider now owns 146,387 shares of the company’s stock, valued at $8,131,797.85. The transaction was disclosed in a filing with the SEC, which is available through this link.
Shares of Abbott Laboratories (ABT) opened at $55.29 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The stock has a market cap of $96,240.00, a PE ratio of 23.05, a price-to-earnings-growth ratio of 2.08 and a beta of 1.55. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.69.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.21% and a return on equity of 7.07%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 earnings per share. equities analysts forecast that Abbott Laboratories will post 2.5 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 87.60%.
COPYRIGHT VIOLATION NOTICE: “Abbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 Shares” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/21/abbott-laboratories-abt-insider-brian-j-blaser-sells-23866-shares.html.
Several equities research analysts have recently commented on ABT shares. Cowen and Company restated a “buy” rating on shares of Abbott Laboratories in a research note on Sunday, September 24th. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research note on Friday, September 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Abbott Laboratories in a research note on Thursday, August 3rd. BidaskClub lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $55.00 price target on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Abbott Laboratories presently has a consensus rating of “Buy” and a consensus target price of $56.81.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Abbott Laboratories by 2.6% during the second quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after acquiring an additional 3,241,063 shares during the period. State Street Corp increased its position in shares of Abbott Laboratories by 18.9% during the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock worth $3,574,987,000 after acquiring an additional 12,806,535 shares during the period. Capital Research Global Investors increased its position in shares of Abbott Laboratories by 45.7% during the second quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after acquiring an additional 14,918,038 shares during the period. Bank of New York Mellon Corp increased its position in shares of Abbott Laboratories by 11.0% during the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock worth $1,500,920,000 after acquiring an additional 3,344,508 shares during the period. Finally, Northern Trust Corp increased its position in shares of Abbott Laboratories by 3.1% during the second quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock worth $1,305,942,000 after acquiring an additional 809,732 shares during the period. 69.99% of the stock is currently owned by institutional investors and hedge funds.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.